2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwang-Il Kim | - |
dc.contributor.author | Sang-Hyun Ihm | - |
dc.contributor.author | Gheun-Ho Kim | - |
dc.contributor.author | Hyeon Chang Kim | - |
dc.contributor.author | Ju Han Kim | - |
dc.contributor.author | Hae-Young Lee | - |
dc.contributor.author | Jang Hoon Lee | - |
dc.contributor.author | Jong-Moo Park | - |
dc.contributor.author | Sungha Park | - |
dc.contributor.author | Wook Bum Pyun | - |
dc.contributor.author | inho Shin | - |
dc.contributor.author | Shung Chull Chae | - |
dc.date.accessioned | 2021-08-02T11:27:15Z | - |
dc.date.available | 2021-08-02T11:27:15Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2019-08 | - |
dc.identifier.issn | 2635-6325 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/13300 | - |
dc.description.abstract | Treatment of hypertension improves cardiovascular, renal, and cerebrovascular outcomes. However, the benefit of treatment may be different according to the patients’ characteristics. Additionally, the target blood pressure or initial drug choice should be customized according to the special conditions of the hypertensive patients. In this part III, we reviewed previous data and presented recommendations for some special populations such as diabetes mellitus, chronic kidney disease, elderly people, and cardio-cerebrovascular disease. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한고혈압학회 | - |
dc.title | 2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations | - |
dc.title.alternative | 2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Gheun-Ho Kim | - |
dc.contributor.affiliatedAuthor | inho Shin | - |
dc.identifier.doi | 10.1186/s40885-019-0123-y | - |
dc.identifier.bibliographicCitation | Clinical Hypertension, v.25, no.4, pp.75 - 88 | - |
dc.relation.isPartOf | Clinical Hypertension | - |
dc.citation.title | Clinical Hypertension | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 75 | - |
dc.citation.endPage | 88 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002578491 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Antihypertensive treatment | - |
dc.subject.keywordAuthor | Blood pressure | - |
dc.subject.keywordAuthor | Cardiovascular complications | - |
dc.subject.keywordAuthor | Cardiovascular risk | - |
dc.subject.keywordAuthor | Guidelines | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.identifier.url | https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-019-0123-y | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.